Bibliografia Curcuma Antinfiammatorio Naturale

La seguente bibliografia è relativa all’articolo “Antinfiammatorio naturale“.

Patologia gastro-intestinale:

1. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study.Dig Dis Sci. 2005;50(11):2191–2193.
2. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(12):1502–1506.
3. Lahiff C, Moss AC. Curcumin for clinical and endoscopic remission in ulcerative colitis. Inflamm Bowel Dis. 2011;17(7):E66.
4. Epstein J, Docena G, MacDonald TT, Sanderson IR. Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br J Nutr. 2010;103(6):824–832.
5. Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study.J Altern Complement Med. 2004;10(6):1015–1018.
6. Shimouchi A, Nose K, Takaoka M, Hayashi H, Kondo T. Effect of dietary turmeric on breath hydrogen.Dig Dis Sci. 2009;54(8):1725–1729.
7. Vecchi Brumatti L, Marcuzzi A, Tricarico PM, Zanin V, Girardelli M, Bianco AM.
   Curcumin and inflammatory bowel disease: potential and limits of innovative treatments.
   Molecules. 2014 Dec 16;19(12):21127-53.
8. Anthwal, A.; Thakur, B.K.; Rawat, M.S.; Rawat, D.S.; Tyagi, A.K.; Aggarwal, B.B. Synthesis, Characterization andin Vitro Anticancer Activity of C-5 Curcumin Analogues with Potential to Inhibit TNF-α-Induced NF-κB Activation. BioMed Res. Int. 2014, 2014, 524161.
9. Lahiff, C.; Moss, A.C.M. Curcumin for clinical and endoscopic remission in ulcerative colitis. Bowel Dis. 2011, 17, E66
10. Moss AC.Curcumin for maintenance therapy in ulcerative colitis. Clin Gastroenterol Hepatol. 2007; 5: 642.
11. Salh, B.; Assi, K.; Templeman, V.; Parhar, K.; Owen, D.; Gómez-Muñoz, A.; Jacobson, K. Curcumin attenuates DNB-induced murine colitis. J. Physiol. Gastrointest. Liver. Physiol. 2003, 285, G235–G243.
12. Hanai, H.; Sugimoto, K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Pharm. Des. 2009, 15, 2087–2094
13. Taylor, R.A.; Leonard, M.C. Curcumin for inflammatory bowel disease: A review of human studies. Med. Re. 2011, 16, 152–156.
14. Rajasekaran, S.A. Therapeutic potential of curcumin in gastrointestinal diseases.World J. Gastrointest. Pathophysiol. 2011, 15, 1–14.

Patologia gastrica:

15. Kim DC, Kim SH, Choi BH, Baek NI, Kim D, Kim MJ, et al. Curcuma longa extract protects against gastric ulcers by blocking H2 histamine receptors. Biol Pharm Bull. 2005;28:2220–4. [PubMed]
16. Repetto MG, Llesuy SF. Antioxidant properties of natural compounds used in popular medicine for gastric ulcers. Braz J Med Biol Res. 2002;35:523–34.
17. . Mei X, Xu D, Wang S, Xu S. Pharmacological researches of curcumin solid dispersions on experimental gastric ulcer. Zhongguo Zhong Yao Za Zhi. 2009;34:2920–3. [PubMed]
18. Zayachkivska OS, Konturek SJ, Drozdowicz D, Konturek PC, Brzozowski T, Ghegotsky MR. Gastroprotective effects of flavonoids in plant extracts. J Physiol Pharmacol. 2005;56:219–31.
19. Rafatullah S, Tariq M, Al-Yahya MA, Mossa JS, Ageel AM. Evaluation of turmeric (Curcuma longa) for gastric and duodenal antiulcer activity in rats. J Ethnopharmacol. 1990;29:25–34
20. Yu Y, Wu S, Li J, Wang R, Xie X, X Yu, Pan J, Xu Y, Zheng L The effect ofcurcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling. Metab Brain Dis. 2015 Feb;30(1):47-55. doi: 10.1007/s11011-014-9554-z. Epub 2014 May 8.
21. Binion DG, Otterson MF, Rafiee P. Curcumininhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut. 2008 Nov;57(11):1509-17. doi: 10.1136/gut.2008.152496. Epub 2008 Jul 2
22. .Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med. 2004;10(6):1015–1018. doi: 10.1089/acm.2004.10.1015.

Uveite:

23. Lal B, Kapoor AK, Asthana OP, Agrawal PK, Prasad R, Kumar P, et al. Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res. 1999;13(4):318–322. doi: 10.1002/(SICI)1099-1573(199906)13:4<318::AID-PTR445>3.0.CO;2-7.
24. Allegri P, Mastromarino A, Neri P. Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up.Clin Ophthalmol. 2010;4:1201–1206.
25. Biswas S, Rahman I. Modulation of steroid activity in chronic inflammation: a novel anti-inflammatory role for curcumin. Mol Nutr Food Res. Epub 2008 Mar 10.
26. Yadav VS, Mishra KP, Singh DP, Mehrotra S, Singh VK. Immunomodulatory effects of curcumin.Immunopharmacol Immunotoxicol. 2005;27(3):485–497.
27. Malchiodi-Albedi F, Matteucci A, Bernardo A, Minghetti L. PPAR-γ, microglial cells, and ocular inflammation: new venues for potential therapeutic approaches. PPAR res . 2008:295784.
28. Murata T, He S, Hangai M, et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41(8):2309–2317.
29. Bonne C. PPAR gamma: a novel pharmacological target against retinal and choroidal neovascularization.J Fr Ophtalmol. 2005;28(3):326–330.
30. Cuomo J, Chernyshev V. Preliminary report–comparative bioavailability of curcuminoids from Meriva® vs 95% curcumin extract. Salt Lake City, UT: Usana Health Sciences, Inc; 2009.
31. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemoter Pharmacol. 2007;60:171–177.
32. Lal B, Kapoor AK, Asthana OP, et al. Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res. 1999;13:318–322
33. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group. Recommendations for the evaluation of intraocular inflammatory diseases. Am J Ophthalmol. 1987;103:234–235.
34. Jurenka J. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Alt Med Rev. 2009;14(2):141–153.
35. Chen M, Hu D-N, Pan Z, Lu CW, Xue CY, Aass I. Curcumin protects against hyperosmoticity-induced IL-1β elevation in human corneal epithelial cell via MAPK pathways. Exp Eye Res. 2010;90(3):437–443.
36. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30(2):85–94.
37. Jeong SJ, Koh W, Lee EO, et al. Antiangiogenic phytochemicals and medical herbs. Phytotherapy Res.2010 Jun 17;
38. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med.1998;4(6):376–383.
39. Kowluru RA, Kanwar M. Effect of curcumin on retinal oxidative stress and inflammation in diabetes.Nutr Metab. 2007;4:8.

Pseudotumor orbitale:

40. Orcutt JC, Garner A, Henk JM, Wright JE. Treatment of idiopathic inflammatory orbital pseudotumours by radiotherapy. Br J Ophthalmol. 1983;67(9):570–574.
41. Lal B, Kapoor AK, Agrawal PK, Asthana OP, Srimal RC. Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother Res. 2000;14(6):443–447.

Reumatologia:

42. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane) Indian J Med Res. 1980;71:632–634.
43. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 2012;26(11):1719–25. doi:10.1002/ptr.4639.
44. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, et al. Product-evaluation registry of Meriva(R), a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med. 2010;52(2 Suppl 1):55–62.
45. .Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, et al. Efficacy and safety of Meriva(R), a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev. 2010;15(4):337–344.
46. Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Phytother Res. 2014
    Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled  trial.
    Nov;28(11):1625-31. doi: 10.1002/ptr.5174. Epub 2014 May 22.
47. Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, Buntragulpoontawee M, Lukkanapichonchut P, Chootip C, Saengsuwan J, Tantayakom K, Laongpech S.Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study.Clin Interv Aging. 2014 Mar 20;9:451-8.
48. Shehzad A, Rehman G, Lee YS.Curcumin in inflammatory diseases.Biofactors. 2013 Jan-Feb;39(1):69-77.
49. Shen CL, Smith BJ, Lo DF, Chyu MC, Dunn DM, Chen CH, Kwun IS.Dietary polyphenols and mechanisms of osteoarthritis.
    J Nutr Biochem. 2012 Nov;23(11):1367-77.
50. Mobasheri A, Henrotin Y, Biesalski HK, Shakibaei M.Scientific evidence and rationale for the development of curcumin and resveratrol as nutraceutricals for joint health.Int J Mol Sci. 2012;13(4):4202-32.
51. Chandran B, Goel A.A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis.Phytother Res. 2012 Nov;26(11):1719-25.
52. Pinsornsak P, Niempoog S.The efficacy of Curcuma Longa L. extract as an adjuvant therapy in primary knee osteoarthritis: a randomized control trial.J Med Assoc Thai. 2012 Jan;95 Suppl 1:S51-8.
53. Shakibaei M, Mobasheri A, Buhrmann C.La curcumina synergizes con resveratrolo per stimolare la via di segnalazione MAPK in condrociti articolari umani in vitro.Geni Nutr . 2011 May; 6 (2): 171-9.
54. Olsen NJ.Nutraceuticals for the treatment of osteoarthritis.Minerva Med. 2011 Feb;102(1):33-40.
55. Henrotin Y, Lambert C, Couchourel D, Ripoll C, Chiotelli E.Nutraceuticals: do they represent a new era in the management of osteoarthritis? – a narrative review from the lessons taken with five products.Osteoarthritis Cartilage. 2011 Jan;19(1):1-21.
56. Csaki C, Mobasheri A, Shakibaei M.Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis.Arthritis Res Ther. 2009;11(6):R165.
57. Biological actions of curcumin on articular chondrocytes.Henrotin Y, Clutterbuck AL, Allaway D, Lodwig EM, Harris P, Mathy-Hartert M, Shakibaei M, Mobasheri A.Biological actions of curcumin on articular chondrocytes.Osteoarthritis Cartilage. 2010 Feb;18(2):141-9.
58. Jurenka JS.Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research.Altern Med Rev. 2009 Jun;14(2):141-53. Review. Erratum in: Altern Med Rev. 2009 Sep;14(3):277.
59. Lev-Ari S, Strier L, Kazanov D, Elkayam O, Lichtenberg D, Caspi D, Arber NCurcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells..Rheumatology (Oxford). 2006 Feb;45(2):171-7. Epub 2005 Oct 25.
60. Deodhar SD, Sethi R, Srimal RC.Preliminary study on antirheumatic activity of curcumin (diferuloyl methane).Indian J Med Res. 1980 Apr;71:632-4.

Diabete e patologie correlate:

61. Zhang DW, Fu M, Gao SH, Liu JL.Curcumin and diabetes: a systematic review.Evid Based Complement Alternat Med. 2013;2013:636053.
62. Soetikno V, Suzuki K, Veeraveedu PT, Arumugam S, Lakshmanan AP, Sone H, Watanabe K.Molecular understanding of curcumin in diabetic nephropathy.Drug Discov Today. 2013 Aug;18(15-16):756-63.
63. Maradana MR, Thomas R, O’Sullivan BJ.Targeted delivery of curcumin for treating type 2 diabetes.Mol Nutr Food Res. 2013 Sep;57(9):1550-6.
64. Wang LL, Sun Y, Huang K, Zheng L.Curcumin, a potential therapeutic candidate for retinal diseases.Mol Nutr Food Res. 2013 Sep;57(9):1557-68.
65. Kapakos G, Youreva V, Srivastava AK.Cardiovascular protection by curcumin: molecular aspects.Indian J Biochem Biophys. 2012 Oct;49(5):306-15.
66. Sahebkar A.Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?Biofactors. 2013 Mar-Apr;39(2):197-208.
67. Meng B, Li J, Cao H.Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications.Curr Pharm Des. 2013;19(11):2101-13.
68. Leiherer A, Mündlein A, Drexel H.Phytochemicals and their impact on adipose tissue inflammation and diabetes.Vascul Pharmacol. 2013 Jan;58(1-2):3-20.
69. Shehzad A, Ha T, Subhan F, Lee YS.New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases.Eur J Nutr. 2011 Apr;50(3):151-61.
70. Alappat L, Awad AB.Curcumin and obesity: evidence and mechanisms.Nutr Rev. 2010 Dec;68(12):729-38.
71. Xia X, Weng J.Targeting metabolic syndrome: candidate natural agents.J Diabetes. 2010 Dec;2(4):243-9.
72. Aggarwal BBTargeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals.Annu Rev Nutr. 2010 Aug 21;30:173-99.
73. Calabrese V, Bates TE, Mancuso C, Cornelius C, Ventimiglia B, Cambria MT, Di Renzo L, De Lorenzo A, Dinkova-Kostova AT.Curcumin and the cellular stress response in free radical-related diseases.Mol Nutr Food Res. 2008 Sep;52(9):1062-73.
74. Bright JJ.Curcumin and autoimmune disease.Adv Exp Med Biol. 2007;595:425-51.
75. Rema M, Pradeepa R.Diabetic retinopathy: an Indian perspective.Indian J Med Res. 2007 Mar;125(3):297-310.
76. Osawa T, Kato Y.Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia.Ann N Y Acad Sci. 2005 Jun;1043:440-51.Retinopatia diabetica
77. Sulaiman RS, Basavarajappa HD, Corson TW.Natural product inhibitors of ocular angiogenesis.Exp Eye Res. 2014 Dec;129:161-71.
78. Jeenger MK, Shrivastava S, Yerra VG, Naidu VG, Ramakrishna S, Kumar A.Curcumin: A pleiotropic phytonutrient in diabetic complications.Nutrition. 2015 Feb;31(2):276-282.
79. Aldebasi YH, Aly SM, Rahmani AH.Therapeutic implications of curcumin in the prevention of diabetic retinopathy via modulation of anti-oxidant activity and genetic pathways.Int J Physiol Pathophysiol Pharmacol. 2013 Dec 15;5(4):194-202.
80. Pescosolido N, Giannotti R, Plateroti AM, Pascarella A, Nebbioso M.Curcumin: therapeutical potential in ophthalmology.Planta Med. 2014 Mar;80(4):249-54.
81. Wang LL, Sun Y, Huang K, Zheng L.Curcumin, a potential therapeutic candidate for retinal diseases.Mol Nutr Food Res. 2013 Sep;57(9):1557-68.
82. Steigerwalt R, Nebbioso M, Appendino G, Belcaro G, Ciammaichella G, Cornelli U, Luzzi R, Togni S, Dugall M, Cesarone MR, Ippolito E, Errichi BM, Ledda A, Hosoi M, Corsi M.Meriva®, a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy.Panminerva Med. 2012 Dec;54(1 Suppl 4):11-6
83. Gupta SK, Kumar B, Nag TC, Agrawal SS, Agrawal R, Agrawal P, Saxena R, Srivastava S.Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms.J Ocul Pharmacol Ther. 2011 Apr;27(2):123-30.
84. Allegri P, Mastromarino A, Neri P.Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumintreatment. Long-term follow-up.Clin Ophthalmol. 2010 Oct 21;4:1201-6.
85. Kowluru RA, Kanwar M.Effects of curcumin on retinal oxidative stress and inflammation in diabetes.Nutr Metab (Lond). 2007 Apr 16;4:8.
86. Balasubramanyam M, Koteswari AA, Kumar RS, Monickaraj SF, Maheswari JU, Mohan V.Curcumin-induced inhibition of cellular reactive oxygen species generation: novel therapeutic implications.J Biosci. 2003 Dec;28(6):715-21

Nefropatia diabetica:

87. Soetikno V, Sari FR, Veeraveedu PT, ThCurcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy.Nutr Metab (Lond). 2011 Jun 10;8(1):35.
88. Khajehdehi P, Pakfetrat M, Javidnia K, Azad F, Malekmakan L, Nasab MH, Dehghanzadeh G.Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study.Scand J Urol Nephrol. 2011 Nov;45(5):365-70.
89. Chiu J, Khan ZA, Farhangkhoee H, Chakrabarti S.Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-kappaB.Nutrition. 2009 Sep;25(9):964-72.
90. Osawa T.Nephroprotective and hepatoprotective effects of curcuminoids.Adv Exp Med Biol. 2007;595:407-23.
91. Wang Y, Wang Y, Luo M, Wu H, Kong L, Xin Y, Cui W, Zhao Y, Wang J, Liang G, Miao L, Cai L.Novel curcumin analog C66 prevents diabetic nephropathy via JNK pathway with the involvement of p300/CBP-mediated histone acetylation.Biochim Biophys Acta. 2015 Jan;1852(1):34-46.
92. Jeenger MK, Shrivastava S, Yerra VG, Naidu VG, Ramakrishna S, Kumar A.Curcumin: A pleiotropic phytonutrient in diabetic complications.Nutrition. 2015 Feb;31(2):276-282.
93. Sun LN, Yang ZY, Lv SS, Liu XC, Guan GJ, Liu G.Curcumin prevents diabetic nephropathy against inflammatory response via reversing caveolin-1 Tyr14 phosphorylation influenced TLR4 activation.Int Immunopharmacol. 2014 Nov;23(1):236-46.
94. Pan Y, Huang Y, Wang Z, Fang Q, Sun Y, Tong C, Peng K, Wang Y, Miao L, Cai L, Zhao Y, Liang G.Inhibition of MAPK-mediated ACE expression by compound C66 prevents STZ-induced diabetic nephropathy.J Cell Mol Med. 2014 Feb;18(2):231-41.
95. Trujillo J, Chirino YI, Molina-Jijón E, Andérica-Romero AC, Tapia E, Pedraza-Chaverrí J.Renoprotective effect of the antioxidant curcumin: Recent findings.Redox Biol. 2013 Sep 17;1(1):448-56.
96. Soetikno V, Suzuki K, Veeraveedu PT, Arumugam S, Lakshmanan AP, Sone H, Watanabe K.Molecular understanding of curcumin in diabetic nephropathy.Drug Discov Today. 2013 Aug;18(15-16):756-63.
97. Huang J, Huang K, Lan T, Xie X, Shen X, Liu P, Huang H.Curcumin ameliorates diabetic nephropathy by inhibiting the activation of the SphK1-S1P signaling pathway.Mol Cell Endocrinol. 2013 Jan 30;365(2):231-40.

Lupus eritematoso sistemico:

98. Khajehdehi P, Zanjaninejad B, Aflaki E, Nazarinia M, Azad F, Malekmakan L, Dehghanzadeh GR.Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study.J Ren Nutr. 2012 Jan;22(1):50-7.
99. Kurien BT, D’Souza A, Scofield RH.Heat-solubilized curry spice curcumin inhibits antibody-antigen interaction in in vitro studies: a possible therapy to alleviate autoimmune disorders.Mol Nutr Food Res. 2010 Aug;54(8):1202-9.
100. Bright JJ.Curcumin and autoimmune disease.Adv Exp Med Biol. 2007;595:425-51.
101. Khajehdehi P, Zanjaninejad B, Aflaki E, Nazarinia M, Azad F, Malekmakan L, et al. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study.J Ren Nutr.2012;22(1):50–57.

Vitiligine:

102. Schallreuter KU, Wood JM, Pittelkow MR, Buttner G, Swanson N, Korner C, et al. Increased monoamine oxidase A activity in the epidermis of patients with vitiligo. Arch Dermatol Res.1996;288(1):14–18.
103. Arca E, Tastan HB, Erbil AH, Sezer E, Koc E, Kurumlu Z. Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo.J Dermatol. 2006;33(5):338–343.

Helicobacter Pylori:

104. Mario F, Cavallaro LG, Nouvenne A, Stefani N, Cavestro GM, Iori V, et al. A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? Helicobacter.2007;12(3):238–243.
105. Koosirirat C, Linpisarn S, Changsom D, Chawansuntati K, Wipasa J. Investigation of the anti-inflammatory effect ofCurcuma longa in Helicobacter pylori-infected patients. Int Immunopharmacol.2010;10(7):815–818

Alzheimer:

106. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res. 2005;2(2):131–136.
107. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease.J Clin Psychopharmacol. 2008;28(1):110–113

Sindrome da immunodeficienza acquisita AIDS:

108.  James JS. Curcumin: clinical trial finds no antiviral effect. AIDS Treat News. 1996;(no 242):1–2.

Psoriasi:

109. Heng MC, Song MK, Harker J, Heng MK. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters.Br J Dermatol. 2000;143(5):937–949.
110. Reddy S, Aggarwal BB. Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase.FEBS Lett. 1994;341(1):19–22.
111. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741
112. Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, Seykora JT, Gelfand JM.Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial.J Am Acad Dermatol. 2008 Apr;58(4):625-31.